Thank you for joining us in 2022!

Kidney Cancer Immunotherapy

Saturday
November 12, 2022, 3:45 pm -
4:15 pm
New treatments to preserve quality of life

Session Description

Coming Soon!

Speaker(s)

Sangeeta Goswami, MD, PhD

The University of Texas MD Anderson Cancer Center

Dr. Sangeeta Goswami is a physician-scientist at the Department of Genitourinary Medical Oncology and the Department of Immunology, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Dr. Goswami obtained her Medical degree from the Gauhati Medical College in Assam, India and PhD in Immunology from the Baylor College of Medicine in Houston, Texas, USA. She completed her Internal Medicine Residency from University of Pittsburgh Medical Center (UPMC) and Medical Oncology Fellowship from MD Anderson Cancer Center. Dr. Goswami has published numerous original research articles and reviews in high-impact journals such as Nature Medicine, Nature Immunology, Science, Nature Reviews Immunology, and Science Translational Medicine which enabled development of novel combination immunotherapy to treat cancer patients. Her clinic is focused on treating patients with renal cell carcinoma and urothelial carcinoma. Her laboratory in the Department of Immunology focuses on understanding the cellular state and plasticity of the tumor-immune ecosystem and its role in determining response to immune checkpoint therapy. Dr. Goswami has designed multiple investigator-initiated clinical trials based on her pre-clinical data and currently leading them as a principal investigator. Recently, she was elected to be a part of the “Extended Leadership Team” for the Break Through Cancer (BTC) GBM team, a research alliance between The University of Texas MD Anderson Cancer Center (MDACC), Dana Farber Cancer Institute, MIT, Johns Hopkins and Memorial Sloan Kettering Cancer Center. As a part of this multi-disciplinary alliance, Dr. Goswami will lead the discovery science work delineating myeloid cell biology to explore therapeutic avenues in GBM. She received numerous awards including Andrew Sabin Award in 2021 for high risk-high impact research for emerging leaders.